

The 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics



01–30 November 2025 | Online

Piperidine Derivatives as Next-Generation Dual Cholinesterase Inhibitors: From Rational In Silico Design to In Vitro Validation

Warda Javed1, Shazia Haider1, Ahsaan Ahmed2, Mehreen Lateef3, Mahrukh Ahmed1, Aisha Iqbal1, Zafar saied saify4 1Department of Pharmaceutcial Chemistry, Faculty of Pharmacy & Pharmaceutical Sciences, University of Karachi, Karachi, 75270, Pakistan 2Institue of Pharmacy, Jinnah Sindh Medical University, Karachi, 75510, Pakistan

3 Department of Biochemistry and Multidisciplinary Research Lab, Bahria University Health Sciences Campus Karachi, 74400, Pakistan

4 International Center for Chemical and Biological Sciences. University of Karachi, Karachi, 75270, Pakistan

70

INTRODUCTION & AIM


Alzheimer's disease (AD) necessitates novel therapeutics. This study aimed to design and develop new heterocyclic cholinesterase inhibitors using a rational, integrated computational and experimental approach, with a focus on achieving potency and selectivity, particularly for butrylcholinesterase (BuChE).

METHOD

Study is divided into three phases.


1-Synthesis

Synthesis of (3S,4R)4-flouromethyl-piperidinemethanol Derivatives and characterization through spectral analysis.



2-In-vitro studies

Ellman's method is use for acetylcholinesterase and butrylcholinesterase inhibitory activity




3-In-silico studies

Molecular modelling of, P8 and p14 against human recombinant acetylcholinesterase (PDB ID: 4EY7), and human recombinant butrylcholinesterase (PDB ID: 4BDS), were carried out to evaluate the ligandprotein interaction using molecular operating environment (MOE 2014) software.



RESULTS & DISCUSSION					
Sr. #	COMPOUND	Acetylcholinesteras e Inhibition Activity IC_{50} (μ M) \pm SEM ^b	Butrylcholinesterase Inhibition Activity IC ₅₀ value(uM)±SEM ^b	Similarity index (SI) ^a (AChE/BuChE)	Preference
1	Lead	32.1 ± 0.56	29.5 ± 0.76	1.088	AChE/BuChE
2	P 1	42.9 ± 0.39	17.5 ± 0.67	2.451	BuChE
3	P 8	29.3 ± 0.56	11.5 ± 0.62	2.547	BuChE
4	P 10	45.4 ± 0.11	30.24 ± 0.14	1.501	BuChE
5	P 12	29.5 ± 0.09	21.5 ± 0.16	1.372	BuChE
6	P 14	26.3 ± 0.11	15.3 ± 0.26	1.718	BuChE
7	P18	54.8 ± 0.22	45.2 ± 0.36	1.21	BuChE
8	P19	61.5 ± 0.51	59.2 ± 0.61	1.038	BuChE(weak)
9	Eserine	5.2 ± 0.18	7.8 ± 0.28	0.667	AChE
10	Donepezil	12.83 ± 0.44	18.66 ± 0.66	0.687	AChE



Docking studies elucidated a binding mode involving anchoring in the catalytic site and π - π interactions in the peripheral site. In vitro testing identified two potent dual inhibitors, P8 ($IC_{50} = 11.5 \mu M$ for BuChE) and P14 ($IC_{50} = 15.3 \mu M$ for BuChE), which outperformed donepezil for BuChE inhibition. The series exhibited a selective profile favoring BuChE. Structure-activity relationship (SAR) confirmed terminal group planarity as critical for potency. All compounds exhibited favorable drug-like properties.

CONCLUSION

The study successfully identifies P8 and P14 as promising, drug-like lead compounds with a superior BuChE-inhibitory profile, making them viable scaffolds for developing next-generation AD therapeutics. The work validates the combined computational and experimental framework for rational inhibitor design

FUTURE WORK / REFERENCES

Islam, M. T., Aktaruzzaman, M., Barai, C., Rafi, F. I., Hasan, A. R., Tasnim, T., Sarder, P., Albadrani, G. M., Al-Ghadi, M. Q., & Sayed, A. A. (2025). In silico screening of naturally derived dietary compounds as butyrylcholinesterase inhibitors for Alzheimer's disease potential treatment. Scientific Reports, 15(1), 17134.

Yekta, R., Sadeghi, L., & Dehghan, G. (2020). The inefficacy of donepezil on glycated-AChE inhibition: Binding affinity, complex stability and mechanism. International Journal of Biological Macromolecules, 160, 35-